Mounjaro vs Zepbound: FDA Indication & Brand Labeling
Mounjaro and Zepbound represent the breakthrough dual GIP and GLP-1 receptor agonist class. Both medications activate natural incretin hormones to suppress appetite, slow gastric emptying, and enhance metabolic efficiency. Because they share identical dosages from 2.5mg up to 15mg per week, choosing between them typically comes down to current stock availability and clinical goals.
Feature-by-Feature Comparison
Mounjaro
Zepbound
| Feature / Capability | Mounjaro | Zepbound |
|---|---|---|
| Active Molecule | Tirzepatide (GIP + GLP-1) | Tirzepatide (GIP + GLP-1) |
| Primary FDA Indication | Type 2 Diabetes & Glycemic Control | Chronic Weight Management (Obesity / Overweight) |
| Dosage Strengths | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Administration | Once-weekly subcutaneous pen | Once-weekly subcutaneous pen |
| Average Weight Reduction | Up to 20-22% in clinical trials | Up to 20-22% in clinical trials |
| Dual Incretin Agonist | ||
| Starting Price | $210.00 – $480.00 | $220.00 – $490.00 |
| View Mounjaro | View Zepbound |
The Final Verdict
Mounjaro and Zepbound contain the exact same active pharmaceutical molecule (tirzepatide) manufactured by Eli Lilly in identical auto-injector pens. Zepbound is specifically packaged and labeled for weight loss, whereas Mounjaro is marketed for diabetes management.
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. The accuracy of pricing and features may change over time. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.
Last updated: September 2026